Avitinib,a new generation inhibitor of epidermal growth factor receptor(EGFR),was approved for clinical trial in both China and the United States,and the phase
Background: Esophageal squamous cell carcinoma(ESCC) is a leading cause of cancer death worldwide and is char?acterized by numerous genetic mutations. TNM stagi
Commonly observed aberrations in epidermal growth factor receptor(EGFR) signaling have led to the development of EGFR-targeted therapies for various cancers,inc